Table 4.
Postoperative outcomes
| Benign disease group (n = 559) | Malignant disease group (n = 1453) | CLM (n = 546) | HCC (n = 450) | Biliary tumours (n = 194) | |
|---|---|---|---|---|---|
| Mortality, n (%) | 39 (50.7%)a | 65 (4.5%) | 9 (1.7%)b | 29 (6.4%) | 16 (8.2%)d |
| Overall morbidity, n (%) | 267 (47.7%)a | 870 (59.9%) | 286 (52.3%)b | 927 (63.8%)c | 146 (75.3%)d |
| Clavien–Dindo class ≥3, n (%) | 97 (17.4%)a | 392 (27%) | 124 (22.7%) | 121 (26.8%)c | 81 (41.8%)d |
| Liver-specific complications, n (%) | |||||
| Pulmonary | 96 (17.1%)a | 120 (21.5%) | 100 (18.4%) | 98 (21.8%) | 54 (27.8%)d |
| Liver failure | 22 (0.4%)a | 39 (2.7%) | 13 (2.4%) | 9 (2.0%)c | 10 (5.2%)d |
| Ascites | 69 (12.4%)a | 135 (24.1%) | 98 (18%)b | 131 (29.1%) | 67 (34.5%)d |
| Biliary fistula | 39 (7.0%) | 113 (7.8%) | 112 (7.7%) | 28 (6.2%)c | 27 (13.9%)d |
| Reoperation, n (%) | 16 (2.9%) | 84 (5.8%) | 51 (3.5%)b | 31 (6.9%) | 16 (8.2%)d |
| Intensive care unit stay, days, mean (range) | 3.9 (1–52)a | 6.1 (1–67) | 5.5 (1–62) | 6.4 (1–57) | 7.4 (1–67)d |
| Hospital stay, days, mean (range) | 11.3 (1–90)a | 14.6 (1–96) | 13.4 (1–82) | 14.2 (3–84)c | 19.5 (2–81)d |
a
Marks a significant difference between the benign and malignant disease groups.
b
Marks a significant difference between CLM and HCC.
c
Marks a significant between HCC and biliary malignancy.
d
Marks a significant difference between biliary malignancy and CLM.
HCC, hepatocellular carcinoma; CLM, colorectal liver metastasis.